Aurinia Pharmaceuticals Inc (AUPH)

[zzaatt]

(excerpt fr. article) "A long road lies ahead for the company"

That refers to KZR!!! Indeed it does!!! A small, open label study, of 17 patients, of whom 4 dropped out (two) with serious side effects.

Two patients had serious side effects — one leaving the trial after worsening pulmonary arterial hypertension, a urinary tract infection and an acute injury, the other staying in after an acute, protracted migraine — with four patients overall dropping out.

I think dancing on the grave of Aurinia is a bit premature! Lupkynis will be a well establish standard of care for LN before KZR is ready to submit their P3 results to the FDA.